{"id":3750,"date":"2025-04-10T09:04:53","date_gmt":"2025-04-10T06:04:53","guid":{"rendered":"https:\/\/relinvestmentsgroup.com\/?p=3750"},"modified":"2025-04-10T09:04:53","modified_gmt":"2025-04-10T06:04:53","slug":"kashiv-biosciences-poluchaet-dolgovoe-finansirovanie-v-razmere-150-millionov-dollarov-ot-goldentree-asset-management","status":"publish","type":"post","link":"https:\/\/relinvestmentsgroup.com\/en\/kashiv-biosciences-poluchaet-dolgovoe-finansirovanie-v-razmere-150-millionov-dollarov-ot-goldentree-asset-management\/","title":{"rendered":"Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management"},"content":{"rendered":"<p><\/p>\n<p class=\"p1\">Kashiv BioSciences, LLC, a fully integrated biopharmaceutical company, today announced that it has entered into a senior secured credit agreement with GoldenTree Asset Management as the sole lender.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\">The $150 million credit facility supports Kashiv BioSciences in advancing its world-class infrastructure, enabling the Company to pursue its research, development, and manufacturing strategy in both the U.S. and India.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\">Kashiv is expanding its state-of-the-art manufacturing facilities in Piscataway, New Jersey and Pipan, India, dedicated to monoclonal antibody (MAB) drug substance manufacturing. The new facility in Pipan, will be one of India\u2019s largest single-use commercial manufacturing facilities of monoclonal antibodies, serving customers in the U.S., Europe, and rest-of-world markets.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\">The new credit facility will also support working capital requirements, research and development, and other business purposes.<\/p>\n<p class=\"p1\">\u201cWe are excited to be working with experienced healthcare investors who share our confidence in the Company\u2019s growth,\u201d said Dr. Sandeep Athalye, Global CEO of Kashiv Biosciences.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\">\u201cThe favorable structure of this debt facility will allow Kashiv to confidently expand its manufacturing capabilities in India and the U.S. and advance its pipeline of biosimilar candidates.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\">This financing comes at a pivotal time of growth and will allow the Company to have the financial flexibility to execute on our near- and long-term growth objectives.\u201d<\/p>\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Kashiv BioSciences, LLC, a fully integrated biopharmaceutical company, today announced that it has entered into a senior secured credit agreement with GoldenTree Asset Management as the sole lender.\u00a0 The $150 million credit facility supports Kashiv BioSciences in advancing its world-class infrastructure, enabling the Company to pursue its research, development, and manufacturing strategy in both the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3751,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3750","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bez-rubriki"],"featured_image_src":{"landsacpe":["https:\/\/relinvestmentsgroup.com\/wp-content\/uploads\/2025\/04\/Money-1-1140x445.webp",1140,445,true],"list":["https:\/\/relinvestmentsgroup.com\/wp-content\/uploads\/2025\/04\/Money-1-463x348.webp",463,348,true],"medium":["https:\/\/relinvestmentsgroup.com\/wp-content\/uploads\/2025\/04\/Money-1-300x208.webp",300,208,true],"full":["https:\/\/relinvestmentsgroup.com\/wp-content\/uploads\/2025\/04\/Money-1.webp",2000,1386,false]},"_links":{"self":[{"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/posts\/3750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/comments?post=3750"}],"version-history":[{"count":1,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/posts\/3750\/revisions"}],"predecessor-version":[{"id":3752,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/posts\/3750\/revisions\/3752"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/media\/3751"}],"wp:attachment":[{"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/media?parent=3750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/categories?post=3750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/relinvestmentsgroup.com\/en\/wp-json\/wp\/v2\/tags?post=3750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}